1. Saito H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen. 2006;13(Suppl 1):S6-7.
2. Nakajima M, Saito H, Soma Y, et al. Prevention of advanced colorectal cancer by screening using the immunochemical faecal 123 J Gastroenterol occult blood test: a case–control study. Br J Cancer. 2003;89:23–8.
3. Saito H, Soma Y, Nakajima M, et al. A case–control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Oncol Rep. 2000;7:815–9.
4. Lee KJ, Inoue M, Otani T, et al. Japan Public Health Centerbased Prospective Study. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev. 2007;31:3–11.
5. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.
6. Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121:3221–9.
7. Sano Y, Byeon JS, Li XB, et al. Colorectal cancer screening of the general population in East Asia. Dig Endosc. 2016;28:243–9.
8. Brown JP, Wooldrage K, Kralj-Hans I, et al. Effect of once-only flexible sigmoidoscopy screening on the outcomes of subsequent faecal occult blood test screening. J Med Screen. 2019;26:11–8.
9. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectalcancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–105.
10. Saltz LB. The value of considering cost, and the cost of not considering value. J Clin Oncol. 2016;34:659–60.
11. Takata K, Fujita KI, Kubota Y, et al. Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan. J Pharm Health Care Sci. 2016;2:30.
12. Sekiguchi M, Igarashi A, Sakamoto T, et al. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score. J Gastroenterol Hepatol. 2020;35:1555–61.
13. Sekiguchi M, Igarashi A, Matsuda T, et al. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data. Jpn J Clin Oncol. 2016;46:116–25.
14. Sekiguchi M, Igarashi A, Sakamoto T, et al. Cost-effectiveness analysis of postpolypectomy colonoscopy surveillance using Japanese data. Dig Endosc. 2019;31:40–50.
15. Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal, appendiceal, and anal carcinoma: the d Secondary. J Anus Rectum Colon. 2019;3:175–95.
16. Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.
17. Yao T, Shiono S. Differences in the pathological diagnosis of colorectal neoplasia between the East and the West: present status and future perspectives from Japan. Dig Endosc. 2016;28:306–11.
18. Kimura S, Sato T, Ikeda S, et al. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20:413–9.
19. Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14:1278–86.
20. Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27:1539–46.
21. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.
22. Yajima S, Shimizu H, Sakamaki H, et al. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy. BMC Health Serv Res. 2016;16:2.
23. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther. 2007;29:2256–67.
24. Miyazaki Y, Harada T, Akase T, et al. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan. Clin Ther. 2009;31:2433–41.
25. Lang K, Lines LM, Lee DW, et al. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEERMedicare data. Clin Gastroenterol Hepatol. 2009;7:198–204.
26. Tramontano AC, Chen Y, Watson TR, et al. Racial/ethnic disparities in colorectal cancer treatment utilization and phasespecific costs, 2000–2014. PLoS ONE. 2020;15:e0231599.
27. Laudicella M, Walsh B, Burns E, et al. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer. 2016;114:1286–92.
28. Ogino M, Kawachi I, Otake K, et al. Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol. 2016;7:158–67.
29. Nakayama T, Imanaka Y, Okuno Y, et al. Analysis of the evidence-practice gap to facilitate proper medical care for the elderly: investigation, using databases, of utilization measures for National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). Environ Health Prev Med. 2017;22:51.
30. Fujii T, Ohisa M, Sako T, et al. Incidence and risk factors of colorectal cancer based on 56 324 health checkups: a 7-year retrospective cohort study. J Gastroenterol Hepatol. 2018;33:855–62.
31. Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:128.